Roche 454 Sequencing Systems successfully resolve genetic mutations in over 4,000 blood cancer cases

Roche 454 Sequencing Systems successfully resolve genetic mutations in over 4,000 blood cancer cases PR Newswire PENZBERG, Germany, December 11, 2012 PENZBERG, Germany, December 11, 2012 /PRNewswire/ -- - International study presented at American Society of Hematology Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual's blood cancer type to guide personalized therapy decisions At the American Society of Hematology Meeting (ASH) Roche announced today the presentation of results from the large scale study IRON-II through an international research consortium. Based on next generation 454 Sequencing Systems from Roche, the study aims to characterize selected genes in individuals with a wide range of hematological malignancies. The consortium of 26 laboratories from 13 countries in Europe and Asia performed comprehensive analysis of 74 genes in individuals with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphatic leukemia (CLL), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). The results from over 4,000 cases demonstrate that the highly advanced technology supports the comprehensive molecular characterization of hematological malignancies with high sensitivity and specificity, with the future prospect of guiding more personalized treatment decisions.